Skip to main content

Advertisement

SpringerLink
Log in

National Trends in the Management of Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia

  • Benign Prostatic Hyperplasia (K McVary, Section Editor)
  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

To gain an understanding of current practices in the management of lower urinary tract symptoms (LUTSs) in the setting of benign prostatic hyperplasia (BPH). Including both medication therapy and emerging minimally invasive options including peri-procedure considerations, expected outcomes, and value-based considerations.

Recent Findings

Medical therapy, primarily alpha blockers (ABs), and 5 alpha reductase inhibitors (5-ARI) remain the most commonly utilized intervention for LUTS associated with BPH. Several minimally invasive surgical treatments (MISTs) have emerged to provide efficacious and durable results, while largely sparing men from the sexual adverse effects of more invasive surgical options. The introduction of value-based health care has led to more cost-conscious medical care and is poised to influence the landscape of LUTS associated with BPH treatment.

Summary

As the population-based and societal needs continue to influence medical care for men with LUTS associated with BPH, a paradigm shift in management is expected.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Abbreviations

MIST:

Minimally invasive surgical treatment

PUL:

Prostatic urethral lift

BPH:

Benign prostatic hyperplasia

LUTS:

Lower urinary tract symptoms

TURP:

Transurethral resection of the prostate

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474–9.

    Article  CAS  Google Scholar 

  2. Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America project: benign prostatic hyperplasia. J Urol. 173:1256.

  3. •• Welliver C, Feinstein L, Ward JB, Fwu CW, Kirkali Z, Bavendam T, et al. Urologic Diseases in America Project. Trends in lower urinary tract symptoms associated with benign prostatic hyperplasia, 2004-2013: the Urologic Diseases in America Project. J Urol. 2019 Jan;203(1):171–178 An excellent evaluation of treatment trends across the US. Though the study period is somewhat dated, this article provides great insight into practice patterns of various healthcare providers for men with symptomatic BPH.

  4. U.S. Census Bureau, Population Projections.

  5. Lepor H. Alpha blockers for the treatment of benign prostatic hyperplasia. Rev Urol. 2007;9(4):181–90.

    PubMed  PubMed Central  Google Scholar 

  6. Izard J, Nickel JC. Impact of medical therapy on transurethral resection of the prostate: two decades of change. BJU Int. 2011;108:89–93.

    Article  Google Scholar 

  7. Kluivers KB, Riphagen I, Vierhout ME, Brolmann HA, de Vet HC. Systematic review on recovery specific quality-of-life instruments. Surgery. 2008;143(2):206–15.

    Article  Google Scholar 

  8. Myles PS, Hunt JO, Nightingale CE, Fletcher H, Beh T, Tanil D, et al. Development and psychometric testing of a quality of recovery score after general anesthesia and surgery in adults. Anesth Analg. 1999;88(1):83–90.

    CAS  PubMed  Google Scholar 

  9. Kava BR, Verbeek AE, Gittelman M, et al. Tamsulosin dispensation patterns in the United States: a real-world, longitudinal, population claims database analysis. Transl Androl Urol. 2019;8(4):329–38.

    Article  Google Scholar 

  10. Vuichoud C, Loughlin KR. Benign prostatic hyperplasia: epidemiology, economics and evaluation. Can J Urol. 2015;22(Suppl 1):1–6.

    PubMed  Google Scholar 

  11. Roehrborn CG, Gange SN, Shore ND, Giddens JL, Bolton DM, Cowan BE, et al. Multi-center randomized controlled blinded study of the prostatic urethral lift for the treatment of LUTS associated with prostate enlargement due to BPH: the L.I.F.T. study. J Urol. 2013;190(6):2161–7.

    Article  Google Scholar 

  12. Foster HE, Barry MJ, McVary KT, et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA Guideline. J Urol. 2018 Sep;200(3):612–619.

  13. Roehrborn CG, Barkin J, Rukstalis DB, et al. Five-year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol. 2017;24(3):88028813.

    Google Scholar 

  14. Gratzke C, Barber N, Speakman M, et al. Prostatic urethral lift vs transurethral resection of the prostate: 2-year results of the BPH6 prospective, multicentre, randomized study. BJU Int. 2017;119:767–75.

    Article  Google Scholar 

  15. McVary KT, Rogers T, Roehrborn CG. Rezum water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia: 4-year results from randomized controlled study. Urology. 2019;126:171–9.

    Article  Google Scholar 

  16. Gilling PJ, Barber N, Bidair M, Anderson P, Sutton M, Aho T, et al. Randomized controlled trial of Aquablation versus transurethral resection of the prostate in benign prostatic hyperplasia: one-year outcomes. Urology. 2019;125:169–73.

    Article  Google Scholar 

  17. Plante M, Gilling P, Barber N, et al. Symptom relief and anejaculation after Aquablation or transurethral resection of the prostate: subgroup analysis from a blinded randomized trial. BJU Int. 2019 Apr;123(4):651–60.

  18. • Nguyen DD, Barber N, Bhoiani N, et al. Waterjet ablation therapy for endoscopic resection of prostate tissue trial (WATER) vs. WATERII: comparing Aquablation therapy for benign prostatic hyperplasia in 30–80 and 80–150 mL prostates. BJU Int. 2020;125(1):112–22 Recent extensive evaluation of waterjet ablation in regards to prostate volume.

  19. Taub DA, Wei JT. The economics of benign prostatic hyperplasia and lower urinary tract symptoms in the United States. Curr Urol Rep. 2006;7(4):272–81.

    Article  Google Scholar 

  20. Porter ME. What is value in health care? NEJM. 2019;363(26):2477–81.

    Article  Google Scholar 

  21. •• DeWitt-Foy ME, Gill BC, Ulchaker JC. Cost comparison of benign prostatic hyperplasia treatment options. Curr Urol Rep. 2019;20:45 This article excellently evaluates the cost comparison and equivalency between various medication and surgical/procedural therapy for BPH.

  22. Ulchaker JC, Martinson MS. Cost-effectiveness analysis of six therapies for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Clinicoecon Outcomes Res. 2018;10:29–43.

    Article  Google Scholar 

  23. Smith C, Craig P, Taleb S, Young S, Golzarian J. Comparison of traditional and emerging surgical therapies for lower urinary tract symptoms in men: a review. Cardiovasc Intervent Radiol. 2017;40:1176–84.

    Article  Google Scholar 

  24. Gill BC, Ulchaker JC. Costs of managing benign prostatic hyperplasia in the office and operating room. Curr Urol Rep. 2018;19(9):72.

    Article  Google Scholar 

  25. Erman A, Masucci L, Krahn MD, Elterman DS. Pharmacotherapy vs surgery as intitial therapy for patients with moderate-to-severe benign prostate hyperplasia: a cost-effective analysis. BJU Int. 2018;122(5):879–97.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Minnesota Urology PA, Minneapolis, MN, USA

    Joseph T. Mahon

  2. Albany Medical Center, Albany, NY, USA

    Charles Welliver

Authors
  1. Joseph T. Mahon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Charles Welliver
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joseph T. Mahon.

Ethics declarations

Conflict of Interest

Joseph Mahon: no disclosures. Charles Welliver: no disclosures.

Human and Animal Rights and Informed Consent

All reported studies/experiments with human or animal subjects performed by the authors were performed in accordance with all applicable ethical standards including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Benign Prostatic Hyperplasia

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mahon, J.T., Welliver, C. National Trends in the Management of Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia. Curr Urol Rep 21, 63 (2020). https://doi.org/10.1007/s11934-020-01014-w

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11934-020-01014-w

Keywords

Search

Navigation